- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 30.06. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.06. | Inhibikase Therapeutics files $300M mixed securities shelf | 1 | Seeking Alpha | ||
| 14.05. | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.05. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.05. | Former Inhibikase leader launches new biotech for midstage Parkinson's asset | 1 | FierceBiotech | ||
| 14.04. | Inhibikase Therapeutics Appoints David McIntyre As CFO, Stock Up In Pre-market | - | RTTNews | ||
| 14.04. | Inhibikase Therapeutics appoints new CFO | 2 | Investing.com | ||
| 14.04. | Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise | 1 | Seeking Alpha | ||
| 14.04. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.03. | H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock | 3 | Investing.com | ||
| 27.03. | Inhibikase Therapeutics GAAP EPS of -$1.16 | 1 | Seeking Alpha | ||
| 27.03. | Inhibikase Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 27.03. | Inhibikase Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity | 411 | GlobeNewswire (Europe) | BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor... ► Artikel lesen | |
| 24.02. | Inhibikase enhances leadership with new appointments | 1 | Investing.com | ||
| 18.02. | Inhibikase Therapeutics: Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth | 189 | GlobeNewswire (Europe) | -- Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON... ► Artikel lesen | |
| 18.02. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.02. | Inhibikase Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 30.01. | Inhibikase hits pause on Parkinson's program over efficacy as it prioritizes lung drug | 1 | FierceBiotech |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 162,40 | -0,37 % | Dividendenbekanntmachungen (15.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,59 USD 0,5058 EUR ABBVIE INC US00287Y1091 1,64 USD 1,4059 EUR ARCOSA INC US0396531008 0,05... ► Artikel lesen | |
| TEVA | 13,800 | -0,36 % | Teva Pharma stock rating reiterated at Buy by BofA on Austedo growth | ||
| EYEPOINT PHARMACEUTICALS | 8,712 | -2,75 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| BAUSCH HEALTH | 5,465 | +0,59 % | Best Stock to Buy Right Now: Bausch Health vs Canopy Growth? | ||
| ORGANIGRAM GLOBAL | 1,220 | -3,17 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 02.04.2025 | The following instruments on XETRA do have their first trading 02.04.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 02.04.2025
Aktien
1 ROMEDLACNOR6 MedLife S.A.
2 CA29872T2092... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 19,900 | 0,00 % | Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress | Los Angeles, California--(Newsfile Corp. - June 18, 2025) - Singular Research, a leading provider of independent research on small-cap companies, today released its analysis of Quantum BioPharma Ltd.'s... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 5,450 | +5,83 % | Astria Therapeutics, Inc.: Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress | -- Q3M Arm Demonstrated 95% Mean Monthly Attack-Rate Reduction -- -- Q6M Arm Demonstrated 86% Mean Monthly Attack-Rate Reduction - -- Well-Tolerated with a Favorable Safety Profile -- --... ► Artikel lesen | |
| AMARIN | 14,000 | +2,19 % | Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus | ||
| NEKTAR THERAPEUTICS | 21,200 | -1,17 % | Nektar Therapeutics Prices $100 Mln Public Offering Of Common Stock At $23.50 Per Share | WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR), a clinical-stage biotech firm specializing in immunotherapy, has priced its underwritten public offering of approximately $100 million in common... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 99,90 | +2,86 % | Deutsche Bank stuft Jazz Pharmaceuticals mit "Buy" ein und sieht attraktiven Einstiegszeitpunkt | ||
| SELLAS LIFE SCIENCES | 1,550 | +1,44 % | SELLAS Life Sciences Group, Inc.: SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study | The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 301,50 | +4,83 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated... ► Artikel lesen | |
| XORTX THERAPEUTICS | 0,774 | -4,68 % | XORTX gibt 3-Millionen-USD-Platzierung bekannt | - Erlös wird für die Weiterentwicklung der XORTX-Programme zur Gichtbehandlung verwendet -
CALGARY, AB, 19. Mai 2025 / IRW-Press / XORTX Therapeutics Inc. ("XORTX" oder das "Unternehmen")... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 40,310 | +0,72 % | BridgeBio Pharma stock maintains Buy rating at H.C. Wainwright after royalty deal | ||
| VERONA PHARMA PLC ADR | 90,20 | -0,22 % | Verona Pharma stock reaches all-time high at 105.0 USD |
Das Unternehmen INHIBIKASE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 1,845 Euro und damit -2,38 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.